Vanguard Health Care ETF vs Simplify Health Care ETF

Vanguard Health Care ETF (VHT) charges 0.09% in expenses versus 0.51% for Simplify Health Care ETF (PINK) and offers a higher dividend yield (1.5% vs 0.6%) with lower beta (0.60 vs 0.73). Over the trailing 12 months, VHT returned 29.3% versus PINK’s 32.4%, with VHT also showing slightly less risk (max drawdown -16.9% vs -18.8%). Portfolio concentration differs materially: VHT holds 411 stocks while PINK holds 58 and concentrates 87% in healthcare, positioning it for higher upside but greater idiosyncratic risk.

Analysis

This is more of a vehicle-selection note than a true healthcare alpha signal. The main mechanism is fee drag versus concentration risk: VHT will likely win over time on a net-return basis if the sector merely stays average, while PINK needs continued manager skill and favorable factor exposure to justify the extra cost. In a sector that already trades on policy and drug-pricing headlines, the cheaper, deeper vehicle is usually the better way to express a broad beta view.

The real winners inside both baskets are the same handful of mega-caps, so the “active vs passive” debate is really a debate about how much single-name risk you want. LLY is the common denominator and should keep attracting incremental ETF flows; HUM is the more important swing factor for PINK because any managed-care miss or reimbursement pressure will hit a concentrated fund harder than a diversified one. The second-order effect is that passive inflows can keep compressing dispersion in large-cap healthcare while leaving smaller thematic funds more exposed to sudden de-rating.

Near term, there is no obvious catalyst to force a decisive relative move unless the next earnings cycle produces a material surprise in obesity, managed care, or drug-pricing commentary. Over 6-18 months, policy headlines and reimbursement decisions matter more than fund branding, and that is where concentration risk becomes dangerous. The contrarian view is that the market may be overpaying for the recent active-outperformance story; a 42 bp expense disadvantage is hard to overcome unless PINK keeps getting the few right names, and that edge can unwind quickly if LLY stalls or HUM improves.

Key Decisions for Investors

• For core healthcare beta over the next 6-18 months, favor VHT over PINK: lower fee, better liquidity, and less path dependency. Use it as the default sector allocation unless you have a specific view on the manager's stock selection.
• Relative-value trade: small long VHT / short PINK position over 3-6 months if the goal is fee capture and mean reversion. Falsify if PINK continues to outperform VHT by more than ~5 percentage points on the next leg up in healthcare.
• Single-name dispersion trade: long LLY vs short HUM into the next 1-2 earnings cycles, using the ETF comparison as confirmation that LLY is the common beneficiary while HUM is the more fragile hold. Reverse if HUM shows margin stabilization or guidance improvement.
• If you do not have a catalyst view, do nothing: the article does not justify chasing either ETF today. Wait for a sector pullback or a policy headline that widens the spread between broad beta and concentrated active exposure.